CN113854559A

CN113854559A - Weight-losing health food and preparation method thereof

Info

Publication number: CN113854559A
Application number: CN202111113289.4A
Authority: CN
Inventors: 陈耀明; 陈伟; 李顺兰
Original assignee: Nutryfarm Chengdu Biomedicine Co ltd
Current assignee: Nutryfarm Chengdu Biomedicine Co ltd
Priority date: 2021-09-23
Filing date: 2021-09-23
Publication date: 2021-12-31

Abstract

The invention provides a weight-losing health food and a preparation method thereof, wherein the health food comprises the following components in parts by weight: 120-160 parts of conjugated linoleic acid glyceride composition, 50-70 parts of green tea extract, 40-60 parts of grape seed extract, 30-60 parts of xylo-oligosaccharide and 25-40 parts of auxiliary material. The weight-reducing health food has scientific compatibility, obvious effect on simple obesity people, safety and no toxic or side effect.

Description

Weight-losing health food and preparation method thereof

Technical Field

The invention belongs to the technical field of health-care food, and particularly relates to weight-losing health-care food and a preparation method thereof.

Background

As the living standard of human society has been increased year by year, the obese and overweight people, WHO have serious diseases in cardiovascular and endocrine metabolism, have been identified as a disease by the World Health Organization (WHO). The fundamental causes of obesity and overweight are that energy intake exceeds energy consumption, and excess energy is converted into fat tissue in the body and accumulated in the body, resulting in a state of weight gain and excess accumulation of fat tissue in the body. For simple obese people, fat reduction and weight loss are main indexes for controlling obesity and keeping health. The fat and weight reduction should not only simply reduce the energy intake, but also adjust the basal metabolic rate of the body to achieve a better balance and virtuous cycle.

As a newly discovered nutrient, Conjugated Linoleic Acid Glycerides (CLAG) have been increasingly studied to show excellent performance in weight control. CLAG can accelerate the rate of fat metabolism, so that fat taken from food can better enter muscle cells and become energy to be utilized; increasing the rate of fat degradation in adipocytes, reducing fat already stored in the body, and reducing body fat. While reducing body fat, CLAG also has the function of avoiding muscle tissue loss, can form virtuous cycle, and really achieves the aims of reducing fat, shaping body and losing weight healthily.

At present, CLAG related weight-reducing products are sold in the market, but the weight-reducing products have more defects, such as CLAG serving as an active ingredient, long administration period, slow effect, unobvious effect in case of small dose, and easily caused side effects such as nausea and vomiting in case of large dose; the existing CLAG compound product has large differences of raw material types, compatible dosages and the like, so that the existing product has uneven effects and is difficult to achieve the expected weight-losing effect. Therefore, a product with scientific, safe and effective compatibility for losing weight is needed.

Disclosure of Invention

The invention aims to provide a weight-losing health-care food with scientific, safe and effective compatibility for simple obese people and a preparation method thereof aiming at the defects of the prior art.

In order to achieve the purpose, the technical scheme adopted by the invention is as follows:

a weight-losing health food comprises the following components in parts by weight: 120-160 parts of conjugated linoleic acid glyceride composition, 50-70 parts of green tea extract, 40-60 parts of grape seed extract, 30-60 parts of xylo-oligosaccharide and 25-40 parts of auxiliary material.

In one embodiment of the present application, the composition comprises the following components in parts by weight: 150 parts of conjugated linoleic acid glyceride composition, 65 parts of green tea extract, 50 parts of grape seed extract, 50 parts of xylo-oligosaccharide and 35 parts of auxiliary material.

In one embodiment of the application, the lotus leaf tea further comprises 15-25 parts of lotus leaf extract and/or chia seed extract 25-35 parts.

In one embodiment of the present application, the composition comprises the following components in parts by weight: 140 parts of conjugated linoleic acid glyceride composition, 50 parts of green tea extract, 40 parts of grape seed extract, 40 parts of xylo-oligosaccharide, 20 parts of lotus leaf extract, 25 parts of chia seed extract and 35 parts of auxiliary material.

In one embodiment of the present application, the conjugated linoleic acid glyceride composition includes conjugated linoleic acid glyceride and one or more of corn syrup, sodium caseinate, ascorbyl palmitate, mixed tocopherol concentrate, silicon dioxide, or dipotassium hydrogen phosphate.

In one embodiment of the present application, the conjugated linoleic acid content of the glycerol conjugated linoleic acid ester composition is greater than or equal to 50.0%;

the content of tea polyphenol in the green tea extract is more than or equal to 60.0 percent;

the content of procyanidine in the grape seed extract is more than or equal to 60.0%.

In one embodiment of the present application, the nuciferine content of the lotus leaf extract is greater than or equal to 90%.

In one embodiment of the present application, the diet health food is a powder, a tablet or a capsule.

A preparation method of a weight-losing health food comprises the following steps:

step S1, respectively crushing the conjugated linoleic acid glyceride composition, the green tea extract, the grape seed extract, the xylo-oligosaccharide, the lotus leaf extract and the chia seed extract, and sieving the crushed materials with a 80-mesh sieve to prepare fine powder for later use;

s2, weighing the conjugated linoleic acid glyceride composition, the green tea extract, the grape seed extract, the xylo-oligosaccharide, the lotus leaf extract and the chia seed extract in the step S1 according to a formula, mixing with auxiliary materials which are sieved by a 80-mesh sieve, and mixing for 30min to prepare mixed powder;

and S3, filling the mixed powder prepared in the step S2 into capsules to obtain capsules with the filling amount of 350 mg/capsule.

In one embodiment of the present application, the conjugated linoleic acid glyceride composition is prepared by the following method: mixing and emulsifying conjugated linoleic acid glyceride, corn syrup, sodium caseinate, ascorbyl palmitate, mixed tocopherol concentrate, silicon dioxide and dipotassium hydrogen phosphate, spray-drying and mixing under the conditions that the air inlet temperature is 180-200 ℃ and the air outlet temperature is 70-80 ℃ to prepare conjugated linoleic acid glyceride composition powder particles;

and/or the presence of a gas in the gas,

the green tea extract is prepared by the following method: taking dry green tea leaves, and mixing the dry green tea leaves according to a solid-liquid mass ratio of 1: 8-12, adding distilled water, extracting for 2-3 times at 95-100 ℃, 1-2 h each time, cooling, filtering, combining filtrates, concentrating under reduced pressure, extracting for 4 times by using 0.5, 0.3 and 0.3 times of ethyl acetate respectively, concentrating and recovering ethyl acetate, concentrating to an appropriate concentration, and spray drying at the air inlet temperature of 130-160 ℃ and the air outlet temperature of 60-90 ℃ to prepare green tea extract powder particles;

and/or the presence of a gas in the gas,

the grape seed extract is prepared by the following method: taking grape seeds, crushing, sieving with a 50-mesh sieve, and mixing according to a solid-liquid mass ratio of 1: 5, adding 65% ethanol solution, and extracting for 2 times with micro-boiling at the temperature of more than or equal to 83 ℃ for 1-2 h each time; filtering, combining filtrates, concentrating under reduced pressure to recover ethanol, concentrating to appropriate concentration, spray drying at air inlet temperature of 150-195 deg.C and air outlet temperature of 95-105 deg.C, and mixing to obtain grape seed extract powder particles;

and/or the presence of a gas in the gas,

the chia seed extract is prepared by the following method: taking chia seeds, crushing, sieving by a 60-mesh sieve, and mixing according to a solid-liquid mass ratio of 1: adding 80% ethanol solution into the mixture for 8-10 times, and extracting for 1-2 hours each time for 2 times; centrifuging the extractive solution at 3000r/min for 10min, and mixing the supernatants; evaporating to dryness in water bath at 60 deg.C to obtain chia seed extract.

Compared with the prior art, the invention has the beneficial effects that:

1. the weight-losing health food adopts the conjugated linoleic acid glyceride composition, the green tea extract, the grape seed extract and the xylo-oligosaccharide for compatibility; the conjugated linoleic acid glyceride composition mainly contains conjugated linoleic acid, and has the functions of reducing cholesterol of a human body, promoting fat consumption and utilization and reducing fat deposition; the main components of the green tea extract comprise tea polyphenol and the like, and the green tea extract has the effects of reducing the content of serum total cholesterol, triglyceride and low-density lipoprotein cholesterol of hyperlipidaemia, and also has the effects of recovering and protecting the function of vascular endothelium, and the effect of reducing the blood fat can effectively avoid rebound of obese people after losing weight; the grape seed extract contains procyanidin as main ingredient, has high antioxidant activity, can remove free radicals, protect tissues from being damaged by the free radicals, reduce cholesterol, prevent arteriosclerosis, prevent cerebral hemorrhage and apoplexy, inhibit thrombosis, reduce fatty liver, and the like; xylo-oligosaccharide improves the taste, can not be digested and utilized by human bodies, and can not increase blood sugar and deposited fat; can also promote the proliferation of probiotics such as bifidobacterium and the like in the intestinal tract to achieve the effect of regulating the intestinal microecology; the health food has reasonable compatibility, appropriate dosage, synergistic effect of components, and effects of reducing fat and weight, and regulating body function, so as to form virtuous circle and prevent rebound after weight reduction.

2. The health food can be added with folium Nelumbinis extract and/or chia seed extract; wherein, nuciferine contained in the lotus leaf extract has strong lipid-lowering effect and body regulation function, and can synergistically enhance the lipid-lowering effect; the chia seed extract is rich in dietary fiber and protein, can improve satiety and resist digestion, and has the effect of stabilizing blood sugar; the lotus leaf extract and chia seed extract can be added to further enhance the weight-losing effect of the weight-losing health food, maintain and promote the health of a human body while losing weight, and achieve the effect of healthy weight-losing.

3. The weight-losing health food has simple preparation method, is easy for batch production, and is convenient for controlling and ensuring the product quality; the prepared capsule is convenient to eat, and the dosage is easy to control, thereby ensuring the efficacy of the product.

4. The weight-losing health-care food shows in a toxicology safety evaluation test that: the MTD of the acute oral toxicity to mice is more than 20g/kg.bw, and the acute oral toxicity belongs to a nontoxic grade; the result of the genotoxicity test is negative; no toxic or side effect on various indexes of rats is generated in the range of the tested dose in the feeding test for 30 days. In a weight-reducing functional animal test, the result indicates that the weight-reducing health food has the function of reducing weight of animals. The results of the human body test food with the weight-reducing function show that the weight-reducing health food has the weight-reducing effect and has no harm to the health of a subject.

Detailed Description

In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is described in further detail below with reference to specific embodiments. It should be understood that the following specific examples are illustrative only and are not intended to limit the invention.

Example 1

A weight-losing health food comprises the following components in parts by weight: 150 parts of conjugated linoleic acid glyceride composition, 65 parts of green tea extract, 50 parts of grape seed extract, 50 parts of xylo-oligosaccharide and 35 parts of auxiliary material. Wherein the auxiliary material is corn starch.

The conjugated glyceryl oleate composition in the components is prepared by the following method: fully mixing conjugated linoleic acid glyceride, corn syrup, sodium caseinate, ascorbyl palmitate, mixed tocopherol concentrate, silicon dioxide and dipotassium hydrogen phosphate, and emulsifying by an emulsifying machine; carrying out spray drying after emulsification, wherein the operating conditions of the spray drying are that the air inlet temperature is 180-200 ℃, and the air outlet temperature is 70-80 ℃; drying, mixing, and making into conjugated linoleic acid glyceride composition powder granule.

Wherein the obtained conjugated linoleic acid glyceride composition is white to off-white powder, the content of conjugated linoleic acid is more than or equal to 50.0%, and the water content is less than or equal to 9%. Corn syrup and sodium caseinate are added for seasoning and thickening; the ascorbyl palmitate and the mixed tocopherol concentrate are added to be used as an antioxidant and a nutrition enhancer, so that the fat solubility and the safety are good; the silicon dioxide and the dipotassium hydrogen phosphate are added, so that the lubricating and material fluidity promoting effects are achieved.

The green tea extract is prepared by the following method: adding distilled water into dry green tea according to a solid-to-liquid ratio of 1:10, extracting for 2 times at 95-100 ℃, each time for 1.5h, cooling, filtering, collecting and combining filtrate obtained by 2 times of filtering, and concentrating under vacuum to 1/5 of about the original volume; then adding 0.5, 0.3 and 0.3 time of ethyl acetate respectively for extraction for 4 times, combining the extract liquor, and vacuum concentrating to recover ethyl acetate; concentrating to a proper concentration, and then carrying out spray drying, wherein the operation conditions of the spray drying are that the air inlet temperature is 130-160 ℃, the air outlet temperature is 60-90 ℃, and drying is carried out to obtain the green tea extract powder particles.

The prepared green tea extract is yellow to brown yellow powder, contains tea polyphenol, caffeine, vitamins and the like, has the content of the tea polyphenol of more than or equal to 60.0 percent, has the effects of reducing the content of serum total cholesterol, triglyceride and low-density lipoprotein cholesterol of hyperlipidaemia, and also has the effects of recovering and protecting the function of vascular endothelium, and the blood fat reducing effect can effectively avoid rebound of obese people after losing weight.

The grape seed extract is prepared by the following method: taking dry grape seeds, crushing, sieving with a 50-mesh sieve, and mixing according to a solid-liquid mass ratio of 1: 5, adding 65% ethanol solution, and extracting for 2 times at 85 deg.C by micro-boiling for 2 hr each time; filtering, collecting and combining filtrate, concentrating under reduced pressure to recover ethanol, then concentrating to an appropriate concentration, and performing spray drying under the operating conditions of air inlet temperature of 150-195 ℃ and air outlet temperature of 95-105 ℃, and mixing the dried substances to obtain the grape seed extract.

The prepared grape seed extract is yellow-brown to reddish-brown powder, contains procyanidine, tea polyphenol, gallic acid and the like, has the content of procyanidine of more than or equal to 60.0 percent, has high-efficiency antioxidant activity, can clear free radicals, protect tissues from being damaged by the free radicals, reduce cholesterol, prevent arteriosclerosis, prevent cerebral hemorrhage and stroke, inhibit thrombosis, reduce fatty liver and the like.

The xylo-oligosaccharide is food-grade xylo-oligosaccharide raw material powder sold in the market, and the content of the xylo-oligosaccharide is more than or equal to 90 percent. Commercially available from Henan Yuan Longne Biotech Ltd.

The weight-losing health food is prepared by mixing the active components and auxiliary materials according to a formula, and can be prepared into powder, pills, granules, tablets, capsules and the like.

Specifically, the preparation method of the weight-losing health-care food capsule comprises the following steps:

and step S1, respectively sieving the conjugated linoleic acid glyceride composition, the green tea extract, the grape seed extract and the xylo-oligosaccharide through a 80-mesh sieve, and preparing into fine powder for later use.

Step S2, accurately weighing 3000g of the conjugated linoleic acid glyceride composition fine powder prepared in the step S1, 1300g of the green tea extract, 1000g of the grape seed extract and 1000g of xylo-oligosaccharide according to the formula, mixing the fine powder with 700g of corn starch auxiliary material sieved by a 80-mesh sieve in a three-dimensional mixer, and mixing for 30min to obtain mixed powder, wherein the water content of the mixed powder is controlled to be less than or equal to 6.0%.

And S3, filling the mixed powder prepared in the step S2 into capsules by using a full-automatic capsule filling machine to prepare capsule granules with the filling quantity of 350 mg/granule.

And step S4, polishing to remove powder on the surface of the capsule, and selecting and removing unqualified capsule particles.

And step S5, filling the mixture into a standard oral solid medicinal high-density polyethylene bottle with the specification of 90 granules per bottle.

And step S6, carrying out external packaging, then inspecting the finished product, and warehousing after the finished product is qualified.

The above steps S1 to S5 are performed in a production plant having a cleanliness of one hundred thousand class.

Through inspection, the weight-losing health food prepared in the embodiment contains per 100 g: 12.2g of tea polyphenol, 9.0g of procyanidine and 22.5g of conjugated linoleic acid.

Example 2

A weight-losing health food comprises the following components in parts by weight: 160 parts of conjugated linoleic acid glyceride composition, 60 parts of green tea extract, 50 parts of grape seed extract, 40 parts of xylo-oligosaccharide and 40 parts of auxiliary materials. Wherein the auxiliary material is starch.

The green tea extract is prepared by the following method: adding distilled water into dry green tea according to a solid-to-liquid ratio of 1:8, extracting for 3 times at 95-100 ℃ for 1h each time, cooling, filtering, collecting and combining filtrate obtained by 3 times of filtering, and concentrating under vacuum to 1/4 of about the original volume; then adding 0.5, 0.3 and 0.3 time of ethyl acetate respectively for extraction for 4 times, combining the extract liquor, and vacuum concentrating to recover ethyl acetate; concentrating to a proper concentration, and then carrying out spray drying, wherein the operation conditions of the spray drying are that the air inlet temperature is 130-160 ℃, the air outlet temperature is 60-90 ℃, and drying is carried out to obtain the green tea extract powder particles.

The grape seed extract is prepared by the following method: taking dry grape seeds, crushing, sieving with a 50-mesh sieve, and mixing according to a solid-liquid mass ratio of 1: 5 adding 65% ethanol solution, and extracting at 90 deg.C for 1.5 hr for 2 times; filtering, collecting and combining filtrate, concentrating under reduced pressure to recover ethanol, then concentrating to an appropriate concentration, and performing spray drying under the operating conditions of air inlet temperature of 150-195 ℃ and air outlet temperature of 95-105 ℃, and mixing the dried substances to obtain the grape seed extract.

Step S2, accurately weighing 3200g of the conjugated linoleic acid glyceride composition fine powder prepared in the step S1, 1200g of the green tea extract, 1000g of the grape seed extract and 800g of xylo-oligosaccharide according to the formula, mixing the fine powder, the green tea extract, the grape seed extract and the xylo-oligosaccharide with 800g of starch auxiliary materials sieved by a 80-mesh sieve in a three-dimensional mixer, and mixing for 30min to obtain mixed powder, wherein the water content of the mixed powder is controlled to be less than or equal to 6.0%.

Through inspection, the weight-losing health food prepared in the embodiment contains per 100 g: 11.3g of tea polyphenol, 8.8g of procyanidine and 23.6g of conjugated linoleic acid.

Example 3

A weight-losing health food comprises the following components in parts by weight: 140 parts of conjugated linoleic acid glyceride composition, 70 parts of green tea extract, 60 parts of grape seed extract, 50 parts of xylo-oligosaccharide and 30 parts of auxiliary materials. Wherein the auxiliary material is corn starch.

The preparation methods and preparation conditions of the conjugated glyceryl oleate composition, the green tea extract and the grape seed extract are the same as those in example 1.

Step S2, accurately weighing 2800g of the fine powder of the conjugated linoleic acid glyceride composition prepared in the step S1, 1400g of the green tea extract, 1200g of the grape seed extract and 1000g of xylo-oligosaccharide according to the formula, mixing with 600g of starch auxiliary materials sieved by a 80-mesh sieve in a three-dimensional mixer, and mixing for 30min to prepare mixed powder, wherein the water content of the mixed powder is controlled to be less than or equal to 6.0%.

Through inspection, the weight-losing health food prepared in the embodiment contains per 100 g: 12.7g of tea polyphenol, 10.6g of procyanidine and 20.4g of conjugated linoleic acid.

Example 4

A weight-losing health food comprises the following components in parts by weight: 140 parts of conjugated linoleic acid glyceride composition, 50 parts of green tea extract, 40 parts of grape seed extract, 40 parts of xylo-oligosaccharide, 20 parts of lotus leaf extract, 25 parts of chia seed extract and 35 parts of auxiliary material. Wherein the auxiliary material is corn starch.

The lotus leaf extract is food-grade lotus leaf extract raw material powder sold in the market, and the nuciferine content of the lotus leaf extract is more than or equal to 90 percent. Purchased from bioscience, Inc., Xianchang Yue, et al.

The chia seed extract is prepared by the following method: taking dried chia seeds, crushing, sieving with a 50-mesh sieve, and mixing according to a solid-liquid mass ratio of 1: adding 80% ethanol solution into 10, mixing, extracting for 2 times (each for 1.5 hr) at 5000r/min, centrifuging for 10min, collecting supernatant, mixing the supernatants, evaporating to dryness in water at 60 deg.C, and pulverizing to obtain chia seed extract.

Specifically, the preparation method of the capsule of the weight-losing health food comprises the following steps:

step S1, respectively sieving the conjugated linoleic acid glyceride composition, the green tea extract, the grape seed extract, the xylo-oligosaccharide, the lotus leaf extract and the chia seed extract with a 80-mesh sieve, and preparing into fine powder for later use.

Step S2, accurately weighing 2800g of the conjugated linoleic acid glyceride composition fine powder prepared in the step S1, 1000g of green tea extract, 800g of grape seed extract, 800g of xylo-oligosaccharide, 400g of lotus leaf extract and 500g of chia seed extract according to the formula, mixing the 2800g of conjugated linoleic acid glyceride composition fine powder with 700g of starch auxiliary material sieved by a 80-mesh sieve in a three-dimensional mixer, and mixing for 30min to prepare mixed powder, wherein the water content of the mixed powder is controlled to be less than or equal to 6.0%.

Through inspection, the weight-losing health food prepared in the embodiment contains per 100 g: 9.2g of tea polyphenol, 7.3g of procyanidine, 20.3g of conjugated linoleic acid and 5.3g of nuciferine.

Example 5

A weight-losing health food comprises the following components in parts by weight: 120 parts of conjugated linoleic acid glyceride composition, 70 parts of green tea extract, 60 parts of grape seed extract, 30 parts of xylo-oligosaccharide, 15 parts of lotus leaf extract, 30 parts of chia seed extract and 25 parts of auxiliary material. Wherein the auxiliary material is corn starch.

The chia seed extract is prepared by the following method: taking dried chia seeds, crushing, sieving with a 50-mesh sieve, and mixing according to a solid-liquid mass ratio of 1: adding 80% ethanol solution 12, mixing, extracting for 2 times (each for 1 hr) at 5000r/min, centrifuging for 10min, collecting supernatant, mixing the supernatants, evaporating to dryness in water at 60 deg.C, and pulverizing to obtain chia seed extract.

Step S2, 2400g of the conjugated linoleic acid glyceride composition fine powder prepared in the step S1, 1400g of green tea extract, 1200g of grape seed extract, 600g of xylo-oligosaccharide, 300g of lotus leaf extract and 600g of chia seed extract are accurately weighed according to the formula, 500g of starch auxiliary material sieved by a 80-mesh sieve is mixed in a three-dimensional mixer, and the mixture is mixed for 30min to prepare mixed powder, wherein the water content of the mixed powder is controlled to be less than or equal to 6.0%.

Through inspection, the weight-losing health food prepared in the embodiment contains per 100 g: 12.1g of tea polyphenol, 10.9g of procyanidine, 17.4g of conjugated linoleic acid and 3.9g of nuciferine.

Example 6

A weight-losing health food comprises the following components in parts by weight: 125 parts of conjugated linoleic acid glyceride composition, 50 parts of green tea extract, 40 parts of grape seed extract, 60 parts of xylo-oligosaccharide, 25 parts of lotus leaf extract, 25 parts of chia seed extract and 25 parts of auxiliary material. Wherein the auxiliary material is corn starch.

Xylo-oligosaccharide and folium Nelumbinis extract are directly purchased.

The preparation method and preparation conditions of chia seed extract were the same as in example 4.

Step S2, accurately weighing 2500g of the fine powder of the conjugated linoleic acid glyceride composition prepared in the step S1, 1000g of green tea extract, 800g of grape seed extract, 1200g of xylo-oligosaccharide, 500g of lotus leaf extract and 500g of chia seed extract according to a formula, mixing with 500g of starch auxiliary material sieved by a 80-mesh sieve in a three-dimensional mixer, and mixing for 30min to prepare mixed powder, wherein the water content of the mixed powder is controlled to be less than or equal to 6.0%.

Through inspection, the weight-losing health food prepared in the embodiment contains per 100 g: 8.7g of tea polyphenol, 7.0g of procyanidine, 17.9g of conjugated linoleic acid and 6.6g of nuciferine.

Example 7

A weight-losing health food comprises the following components in parts by weight: 130 parts of conjugated linoleic acid glyceride composition, 50 parts of green tea extract, 55 parts of grape seed extract, 45 parts of xylo-oligosaccharide, 35 parts of chia seed extract and 35 parts of auxiliary material. Wherein the auxiliary material is corn starch.

Xylo-oligosaccharide and folium Nelumbinis extract are directly purchased.

Step S2, 2600g of the conjugated linoleic acid glyceride composition fine powder prepared in the step S1, 1000g of green tea extract, 1100g of grape seed extract, 900g of xylo-oligosaccharide and 700g of chia seed extract are accurately weighed according to the formula, 700g of starch auxiliary material sieved by a 80-mesh sieve is mixed in a three-dimensional mixer for 30min to prepare mixed powder, and the water content of the mixed powder is controlled to be less than or equal to 6.0%.

Through inspection, the weight-losing health food prepared in the embodiment contains per 100 g: 8.6g of tea polyphenol, 9.5g of procyanidine and 18.7g of conjugated linoleic acid.

Example 8

A weight-losing health food comprises the following components in parts by weight: 145 parts of conjugated linoleic acid glyceride composition, 55 parts of green tea extract, 45 parts of grape seed extract, 45 parts of xylo-oligosaccharide, 25 parts of lotus leaf extract and 35 parts of auxiliary material. Wherein the auxiliary materials are microcrystalline cellulose and silicon dioxide.

Xylo-oligosaccharide and folium Nelumbinis extract are directly purchased.

Step S2, accurately weighing 2900g of the conjugated linoleic acid glyceride composition fine powder prepared in the step S1, 1100g of green tea extract, 900g of grape seed extract, 900g of xylo-oligosaccharide and 500g of lotus leaf extract according to the formula, mixing 700g of auxiliary materials sieved by a 80-mesh sieve in a three-dimensional mixer, and mixing for 30min to obtain mixed powder, wherein the water content of the mixed powder is controlled to be less than or equal to 6.0%.

Through inspection, the weight-losing health food prepared in the embodiment contains per 100 g: 9.5g of tea polyphenol, 7.7g of procyanidine, 20.8g of conjugated linoleic acid and 6.5g of nuciferine.

Example 9

Toxicology safety evaluation test

First, acute oral toxicity test (maximum tolerated dose method, i.e. MTD method)

The test substance is the capsule prepared in example 4, the content of the capsule is brown yellow to brown powder, the specification is 350 mg/capsule, the recommended dosage for oral administration of an adult is 2 times per day and 3 capsules per time, and the adult weight is calculated according to 60kg and is 35mg/kg. The capsule contents were taken for testing.

The SPF-grade Kunming mice (provided by Guangxi medical university laboratory animal center) are 20 mice, 18-22 g in weight and half in sex. Animals were fasted for 16 hours before the test, without any restriction on water. Weighing 20.0g of the test substance, adding pure water to 40mL, mixing uniformly to prepare a suspension with the concentration of 500mg/mL, and then performing intragastric administration on the animal for 2 times (at intervals of 6 h), wherein the intragastric administration amount is 0.4mL/20g.bw each time, and the total dose is 20000 mg/kg.bw. And observing and recording the poisoning expression of the animals after the gavage. Weigh once a week, observe for a two week period, dissect animals for gross observation at the end of the trial. The test substance is evaluated for acute toxicity according to toxicity grading standards.

The results of the acute oral toxicity test of the weight-reducing health food are shown in table 1, and after the sample with the dosage of 20000mg/kg.bw is administered to the mouse for gastric lavage, the animal grows well, and the weight is not influenced. None of the tested mice had toxic symptoms and no animal death was observed for 14 days. After the experiment, animals are dissected and generally observed, and no obvious abnormal changes are seen in main organs such as liver, kidney, spleen, heart, lung, stomach, intestine and the like. The result shows that the weight-losing health-care food has the acute oral toxicity MTD of more than 20g/kg.bw to mice, and the acute oral toxicity belongs to a nontoxic grade.

Second, genotoxicity test

1. Contaminant mutagenicity detection assay (Ames assay)

The test substance is the capsule preparation prepared in example 4, the content is brown yellow to brown powder, the specification is 350 mg/capsule, the recommended dosage for adult oral administration is 2 times per day and 3 capsules per time, the adult body weight is calculated according to 60kg, and the converted dosage is 35mg/kg. The capsule contents were taken for testing.

The test is carried out by four strains of Salmonella typhimurium histidine-deficient type TA97a, TA98, TA100 and TA102 which are identified to meet the requirements. Because the conjugated linoleic acid glyceride contained in the test substance is difficult to dissolve in water, dimethyl sulfoxide is used as a solvent. Weighing 5.0g of a test substance, adding dimethyl sulfoxide to 100mL, mixing uniformly to prepare a 50 mg/mL concentration solution, sequentially diluting by 5 times (taking 10mL and adding dimethyl sulfoxide to 50 mL) to prepare 10, 2, 0.4 and 0.08 mg/mL concentration solutions respectively, and treating the test solution for test after autoclaving (0.103Mpa 20 min). Rat liver microsomal enzyme induced by polychlorinated biphenyl (S9) was used as an in vitro metabolic activation system. By adopting a plate doping method, 0.1mL of test strain enrichment liquid, 0.1mL of test substance solution and 0.5mL of S9 mixed solution (when metabolic activation is needed) are sequentially added into the heat-preserved top layer culture medium, mixed uniformly and poured onto a bottom layer culture medium plate. The 5 test doses were 5000, 1000, 200, 40, 8 ug/dish, respectively, with spontaneous reversion control, solvent control and positive mutagen control. The spontaneous reversion control was identical to the sample group except that no sample was added. Solvent control samples were replaced with dimethyl sulfoxide and the remaining conditions were the same as for the sample set. Each strain of each dose group was plated in 3 parallel dishes. The culture was incubated at 37 ℃ for 48 hours, and the number of colonies per dish was counted. The whole set of experiments was repeated twice under the same conditions. If the number of the test object's recurrent colonies increases more than 2 times of the number of the spontaneous recurrent colonies and has a dose-response relationship, the test object is positive for the mutagenesis test.

The test results of the Ames test are shown in table 2 and table 3, and for the four test strains of TA97a, TA98, TA100 and TA102, the number of the reversion colonies of each dose group of the sample does not exceed twice of the number of the spontaneous reversion colonies regardless of whether S9 is added, and no dose-response relation exists, which indicates that the test result of the mutagenesis test of the test object is negative.

And (4) conclusion: the weight reducing health food has no effect of inducing test strain reversion.

2. Micronucleus test for myelophilis pleochromocytes

The test was performed by oral gavage with two 24 hour intervals. 50 Kunming mice (provided by Guangxi medical university laboratory animal center) with the weight of 25 g-30 g are selected and randomly divided into 5 groups, wherein each group comprises 10 mice and each half of the mice is male and female. 10000, 5000 and 2500 mg/kg.bw of 3 doses in the test group respectively, pure water is used as a negative control, and cyclophosphamide (cp) with the dose of 40mg/kg.bw is used as a positive control. Respectively weighing 20.0g, 10.0 g and 5.0g of test substances, adding pure water to 40mL, mixing uniformly to prepare suspension with the concentration of 500 m/mL, 250 m/mL and 125 m/mL, then intragastrically feeding the animals according to the volume of 0.4mL/20g.bw, feeding a negative control group with the same volume of pure water, and feeding a positive control group with the same volume of 2 mg/mL cyclophosphamide solution. Animals were sacrificed by cervical leukosis 6 hours after the second sample application, and sternal bone marrow was taken and smeared with calf serum dilution, fixed in methanol, and stained with Giemsa. Counting 1000 Pleochromocyte (PCE) cells of each animal under an optical microscope, and observing the number of the PCE cells containing microkernels, wherein the microkernel rate is measured by PCE thousandths containing microkernels; 200 pleochromocytes were counted simultaneously, and the ratio of pleochromocytes to mature erythrocytes (PCE/NCE) was calculated. If the micronucleus rate of the test group is higher than that of the negative control group, and the micronucleus rate has obvious dose-response relation and statistical significance, the result is the positive result.

The results of the test of the weight-reducing health food on mouse myelopleochromocytoblast micronucleus are shown in table 4, when the micronucleus rates of the bone marrow cells of mice of each dose group of the test object are compared with that of a negative control group, the difference is not significant (P >0.05), the PCE/NCE values of each dose are in a normal value range, the PCE/NCE values of each dose group are not less than 20% of that of the negative control group, and the difference is not significant when the micronucleus rates of a cyclophosphamide positive control group and that of the negative control group are significant (P <0.01), which indicates that the weight-reducing health food has no damage and inhibition effect on the bone marrow cells of the mice.

3. Mouse teratospermia test

50 Kunming male mice with the weight of 25 g-35 g are selected and randomly divided into 5 groups of 10 mice. 10000, 5000 and 2500 mg/kg.bw of 3 doses in the test group respectively, pure water is used as a negative control, and cyclophosphamide (cp) with the dose of 40mg/kg.bw is used as a positive control. Respectively weighing 20.0g, 10.0 g and 5.0g of samples, adding pure water to 40mL, mixing uniformly to prepare 500mg/mL, 250 mg/mL and 125 mg/mL suspension, then intragastrically feeding animals according to the volume of 0.4mL/20g.bw, feeding a negative control group with the same volume of pure water, and feeding a positive control group with the same volume of 2 mg/mL cyclophosphamide solution. Gavage was performed once a day for 5 consecutive days. Animals were sacrificed on day 30 after the last sample, epididymal sperm smears were removed, fixed in methanol, and stained with eosin. Under an optical microscope, 1000 whole sperm were counted per animal and sperm teratogenicity rate was calculated. If the sperm aberration rate of the test group is higher than that of the negative control group, the statistics shows significant significance, and the positive result is obtained through the dose response relation.

The results of the test of the health food for reducing the weight on mouse teratospermia are shown in table 5, the incidence rate of the tested substance on mouse teratospermia is not obviously changed, the teratospermia rate of each dosage group of the sample is not significant (P is more than 0.05) compared with that of a negative control group, and the difference between a cyclophosphamide positive control group and the negative control group is very significant (P is less than 0.01), which indicates that the health food for reducing the weight does not have the effect of generating the aberration on the sperms of male mice.

Three, rat 30 days feeding test

80 SPF SD rats (provided by Guangdong provincial medical experiment animal center) are selected, and the weight of each of the female and male rats is 60-80 g. Animals were randomly divided into 4 groups, negative control and 3 test groups of 20 animals each with male and female halves. The doses of the 3 test groups are respectively set to be 3500, 1750 and 875 mg/kg.bw, which respectively correspond to 100, 50 and 25 times of the recommended dose of the human body. 35.00 g, 17.50 g and 8.75g of test substances are respectively weighed, pure water is added to 100mL, the mixture is uniformly mixed to prepare suspension with the concentration of 350.0 mg/mL, 175.0 mg/mL and 87.5 mg/mL, animals with corresponding dose are irrigated with stomach according to the volume of 1.0mL/100g.bw, the negative control group is irrigated with pure water with the same volume, and the stomach is irrigated once a day for 30 days continuously.

All animals were given plain feed, single-cage fed, free to ingest drinking water during the experiment. The animals were observed daily for activity and growth, and fed 2 times a week, the food intake and food remaining were recorded, the body weight was weighed once a week, and the food intake and food utilization rate per week were calculated. After the experiment is finished, animals are fasted overnight (fasted for 16h without water), then the animals are weighed to be empty stomach, rats are killed, 2 blood samples are collected, and one blood anticoagulation is carried out to detect Hb, RBC, WBC and classification thereof, PLT and the like by using a blood counting instrument; and (3) separating serum from the other blood anticoagulation, and detecting the serum AST, ALT, BUN, Cr, TC, TG, Glu, TP, Alb and other items by using a kit and a full-automatic biochemical analyzer. After blood collection, animals are dissected, general observation is carried out, organs such as liver, kidney, spleen, testis and the like are taken for weighing, the organ/body ratio is calculated, and the organs such as liver, kidney, spleen, stomach, duodenum, testis, ovary and the like are taken for pathological histological examination. When general examination of animals in each dose group shows no obvious lesion and no change of biochemical indexes, histopathological examination of main organs of animals in the high dose group and the control group is only carried out, and corresponding organs and tissues of the medium and low dose groups are examined if lesions are found.

(1) During the experiment, the animals in each group grow well, abnormal behaviors and poisoning manifestations of the animals are not seen, and the animals in each group do not die.

(2) Influence of weight-reducing health food on weight and food utilization rate of rat

The results of body weight and food availability of each dose group throughout the test period are shown in table 6 and table 7, rats were gavaged with 3500, 1750, 875 mgkg. bw doses of the test substance for 30 days, and the weekly body weight, weight gain, total food intake and total food availability of the male and female rats of each dose group of the sample during the test period were compared with those of the control group, and the differences were not significant (P >0.05), indicating that the sample had no significant effect on the body weight gain and food availability of the rats.

(3) Influence of weight-reducing health food on conventional index of rat blood

As shown in table 8 and table 9, when rats were gavaged with weight-reducing health food at 3500, 1750, 875 mg/kg. bw dosage for 30 days, hemoglobin, total number of erythrocytes, total number of leukocytes, classification thereof, and platelet number of female and male rats in each dosage group were compared with those in the control group, and the differences were all insignificant (P >0.05), indicating that the test substance had no significant effect on the blood routine index of rats.

(4) Influence of weight-reducing health food on biochemical index of blood of rat

As shown in table 10 and table 11, when rats were gavaged with weight-reducing capsules at 3500, 1750, 875 mg/kg.bw for 30 days, the differences between serum glutamic-oxaloacetic transaminase, glutamic-pyruvic transaminase, urea nitrogen, creatinine, cholesterol, triglyceride, total protein, albumin, and blood sugar of female and male rats in each dose group of the test substances and the control group were not significant (P >0.05), which indicates that the test substances had no significant effect on the biochemical indicators of blood of rats.

(5) Influence of weight-reducing health food on weight of rat viscera and ratio of viscera to body weight

As shown in table 12 and table 13, when rats were gavaged with the diet health food at 3500, 1750, 875 mg/kg. bw doses for 30 days, the difference between the liver, kidney, spleen, testis weight and liver/body, kidney/body, spleen/body, testis/body ratio of male rat and control group was not significant (P >0.05), which indicates that the test substance had no significant effect on the organ weight and organ/body ratio of rats.

(6) Gross anatomical observation and histological examination results

At the end of the experiment, animals were dissected and no obvious lesions were found in any group of animals by gross observation. Therefore, only the major organs of the high dose group and the negative control group of the samples were selected for histopathological section examination (experimental data omitted). The results show that liver lobules of 1 male rat and 1 female rat in the high dose group and the control group have liver lobules with slight steatosis of liver cells, liver lobules of 1 male rat and 1 female rat in the high dose group and 2 male rat and 1 female rat in the control group have liver lobules with punctate necrosis, and liver sink areas of 2 male rat and 1 female rat in the high dose group and 1 male rat and 2 female rat in the control group have small inflammatory cell infiltration; the interstitial substance of the renal cortex of rats with 1 female and 1 female in the high dose group and 2 male and 1 female in the control group was observed to have a small amount of inflammatory cell infiltration. The tissue lesions belong to spontaneous light lesions of animals, and the tissue lesions of the two groups of animals have similar degrees, so the tissue lesions can be eliminated from being caused by tested substances, and other visceral organs and tissues have no pathological histological change, which shows that the weight-reducing health food has no damage to the visceral organs and tissues of rats.

In conclusion, after the weight-reducing health food with the dosage of 20000mg/kg.bw is administrated to mice for gastric lavage, no toxic symptom and death of animals are seen, the acute oral toxicity MTD of the weight-reducing health food to the mice is more than 20g/kg.bw, and the acute oral toxicity belongs to a non-toxic grade.

The results of the three genotoxicity tests (Ames test, mouse bone marrow cell micronucleus test and mouse sperm malformation test) are all negative.

Feeding the rats for 30 days for a feeding experiment, wherein the rats are continuously subjected to intragastric administration for 30 days by using weight-reducing health-care food with 3 doses of 3500, 1750 and 875 mg/kg.bw (respectively equivalent to 100, 50 and 25 times of the recommended dose of a human body), the growth and development of animals are good during the experiment, and the weight, the weight gain, the food intake, the food utilization rate, the blood conventional index, the blood biochemical index, the visceral organ weight, the visceral organ/weight ratio and the like of the rats in each dose group are not obviously influenced; gross anatomical observations and histopathological examination revealed no abnormal changes associated with the subjects. No toxic or side effect of the test substance on various observation indexes of rats is found in the range of the tested dose. The weight-losing health-care food is safe and free of toxic and side effects when used in a recommended dose.

Example 10

Animal experiment for weight loss

Materials and methods

The test substance is the capsule prepared in example 1, the content of the capsule is brown yellow to brown powder, the specification is 350 mg/capsule, the recommended dosage for oral administration of an adult is 2 times per day and 3 capsules per time, and the adult weight is calculated according to 60kg and is 35mg/kg. The capsule contents were taken for testing.

The SPF SD male white rats (provided by Guangxi medical university laboratory animal center) weigh 70 rats and 180-220 g.

According to the recommended dosage of the sample for human body, the dosages of 3 test groups are respectively set as 700, 350 and 175 mg/kg.bw (respectively corresponding to 20, 10 and 5 times of the recommended dosage for human body), and a blank control group and an obesity model control group (hereinafter referred to as "model control group") are additionally arranged, and each group contains 10 animals. Respectively weighing 14.0 g, 7.0g and 3.5g of samples, adding pure water to 200 mL, mixing uniformly to prepare 70.0 mg/mL, 35.0 mg/mL and 17.5 mg/mL suspension, feeding the corresponding dose of animal intragastric test solution according to the volume of 1.0mL/100g.bw in an oral mode, feeding the blank control group and the model control group with the same volume of pure water, performing intragastric administration once a day, and continuously performing intragastric administration for 6 weeks.

The method for preventing obesity is adopted: rats were fed maintenance diet under the barrier system for 7 days, and after the end of the acclimation period, they were randomly divided into 2 groups by body weight, wherein 10 rats were given maintenance diet as a blank control group and 60 rats were given high-calorie diet as a high-fat diet group. The food intake, food amount scattered, and food remaining amount were recorded every week, and the body weight was weighed 1 time. After feeding for 2 weeks, rats in the high-fat diet group were ranked according to weight gain, and 1/3 obesity-resistant rats with lower weight gain were eliminated. The screened 40 obesity-sensitive rats were randomly divided into 4 groups by body weight, which were a model control group and three dose groups, respectively. The model control group and the three dose groups were given high calorie model feed and the blank control group was given maintenance feed. Each dose group was gavaged with a different dose of test sample, the model control group and the blank control group were given an equal volume of purified water, and the test sample was given for 6 weeks. The food intake, food amount scattered, and food remaining amount were recorded every week, and the body weight was weighed 1 time. After the test was completed, the body weight was weighed, 1% sodium pentobarbital (0.5mL/100g BW) was anesthetized, perirenal fat and peritesticular fat were dissected and taken out, and the fat/body ratio was calculated.

And (4) judging a result: the weight or weight gain of the experimental group is lower than that of the model control group, the in vivo fat weight or fat/body ratio is lower than that of the model control group, the difference is significant, the food intake is not significantly lower than that of the model control group, and the positive result of the test on the weight-reducing function of the tested sample animal can be judged.

Second, result in

(1) Influence of weight-reducing health food on weight and food utilization rate of rat

As shown in tables 14 and 15, the body weights of the rats in the pre-molding high-fat diet group and the blank control group were consistent, and the difference was not significant. After the rats fed with the high-calorie diet for 2 weeks, the weight and the weight gain of the rats in the high-fat diet group are greater than those of the rats in the blank control group, the weight and the weight gain of the rats in the two groups have significance (P <0.05), the food intake of the rats in the two groups has no obvious difference (P >0.05), and the food utilization rate of the rats in the high-fat diet group is higher than that of the rats in the blank control group (P < 0.05).

As shown in table 14 and table 15, when the experiment is initially divided, the rat body weight of the model control group is larger than that of the blank control group (P <0.01), and the rat body weight of each dose group of the test substance has no significance (P >0.05) with respect to the difference between the model control group.

As shown in tables 16 to 22, after the start of the experiment, the weekly and final body weights of the model control group were both greater than those of the blank control group, and the difference was very significant (P <0.01), and the difference in total weight gain of the two groups was also very significant (P <0.01), indicating that the obesity model was established. After the experiment begins, the weight increase of each dose group of the test object is smaller than that of the model control group, and the weekly weight gain and the total weight gain of the high dose group have significance with the difference of the model control group (P < 0.05). The total caloric intake and total food utilization of the model control group were greater than the blank control group, and the differences were all very significant (P < 0.01); compared with the model control group, the weekly food intake, the total food intake and the total caloric intake of each dose group of the tested substances have no significance (P >0.05), and the weekly food utilization rate and the total food utilization rate of the high dose group are smaller than those of the model control group, and the significance is shown in the difference (P <0.05 or P < 0.01). The results show that the test substance has the effect of inhibiting the weight gain of the rat in the obesity model, and probably inhibits the weight gain of the rat by reducing the food utilization rate of the rat.

That is, the weight-reducing health food with the dosages of 700, 350 and 175 mg/kg.bw (respectively equivalent to 20, 10 and 5 times of the dosage recommended by a human body) is continuously infused into the obese model rat for 6 weeks, so that the weight increase of the obese model rat can be inhibited, the food utilization rate of the obese model rat is reduced, the fat accumulation in the body of the obese model rat is reduced, the food intake of an animal is not obviously influenced, and the weight-reducing health food is prompted to have the function of reducing the weight of the animal.

Example 11

Human body test for fat-reducing function

Materials and methods

(1) The test substance is the capsule prepared in example 1, the specification is 350 mg/capsule, and the recommended dosage for adult oral administration is 2 times per day, 3 capsules per time. The package, appearance and specifications of the placebo were consistent with the samples.

(2) A subject: the Body Mass Index (BMI) of the simple obese people with the age of 18-65 is more than or equal to 30, or the percentage of total fat reaches: > 25% in men and > 30% in women.

Subject exclusion criteria: a. patients with serious diseases of heart, liver, kidney and hemopoietic system and mental disease; b. pregnant or lactating women, and those allergic to the subject; c. taking articles related to the tested function in a short time affects the judgment of the result; d. if the test substance is not eaten according to the regulations, the efficacy or the safety judgment cannot be judged if the efficacy or the data are not complete.

(3) Grouping: adopting self-control and inter-group control test design, namely dividing into a test food group and a control

And (4) grouping. Randomly dividing the selected tested population into 2 groups according to the weight and the body fat weight, wherein the number of people entering effective statistics in each group at the end of the test is not less than 50.

(4) The edible dosage and the method are as follows: the trial group people take the medicine orally 2 times a day, 3 granules each time, and take the medicine continuously for 60 days. The control group adopts placebo control, the administration method is the same as that of the test group, and the administration period is 60 days.

(5) Observation indexes are as follows:

A. safety index

a. General conditions: including mental, sleep, diet, stool and urine, heart rate, blood pressure, etc.

b. Blood routine, urine routine, stool routine examination: before the test, the test is finished.

c. Biochemical indexes of liver and kidney function blood are measured: comprises serum albumin, total protein, glutamic-oxaloacetic transaminase, glutamic-pyruvic transaminase, urea nitrogen, creatinine, blood sugar, blood uric acid and urine ketone body, and is tested once before and after the test.

d. Chest X-ray, electrocardiogram, B-ultrasound of abdomen: one transthoracic, electrocardiographic, and abdominal B-ultrasound examination was performed prior to the start of the experiment.

e. And (3) testing the exercise endurance: the testee steps on the power bicycle with the same resistance load before and after the test, and the preset exercise power is as follows: the 5 th minute exercise heart rate was recorded for both men and women at 100 watts and the maximum oxygen consumption (L/min) was determined indirectly for each subject using Astrand and Ryhming nomograms.

f. Other adverse reactions were observed: such as anorexia, diarrhea, etc.

g. Dietary factor and exercise profile observations

The subjects were asked to follow the diet as closely as possible before starting and ending the trial on the test samples for three days.

The inquiry and observation of the exercise condition of the subject during the test are required to be consistent with the daily exercise condition.

B. Index of efficacy

a. Measuring height and weight, and calculating standard weight and overweight degree

Adult standard body weight (Kg) = (height (cm) -100) × 0.9

Body Mass Index (BMI) = weight (kg) ÷ height 2(m2)

Supergravity (%) = [ (measured body weight-standard body weight) ÷ standard body weight ] × 100%

b. The total body fat (kg) and the percentage (%) of fat were measured using a human fat analyzer (Japanese TANITATBF-410A human body composition analyzer).

c. Thickness of subcutaneous fat: the skin caliper method was used to measure the position according to Table 23.

(6) And (4) judging a result: compared with a test group and a control group after test, the weight of fat in the body is reduced, at least 2 points of 4 points of subcutaneous fat are reduced, one of waistline and hip circumference is reduced, the difference is significant (P is less than 0.05), exercise endurance is not reduced, no adverse effect is caused on the health of the organism, the influence of diet and exercise on the weight-reducing function is eliminated, and the tested sample can be judged to have the weight-reducing function.

Second, result in

(1) Basic condition of human group

120 simple obese people are divided into two groups to carry out a weight-reducing function test diet test, 11 people are quitted, missed and taken without requirements after the test is finished, the loss rate is 9.2%, and the effective statistics of 53 people in a control group, 22 people in a male group, 31 people in a female group, 56 people in a test diet group, 27 people in the male group and 29 people in the female group are finally carried out. As shown in Table 24, there was no significant difference in height, weight and body fat weight average between the two groups of people before the test (P > 0.05).

(2) Safety observation index

a. General conditions: including mental, dietary, sleep, stool and urine, heart rate, blood pressure, etc.

During the test period, the two groups of subjects were normal in spirit, and had no abnormality in diet, sleep, and urination and defecation.

The subject is inquired about the diet three days before the test sample begins and finishes, the daily diet and the exercise condition are basically consistent, and the statistical data is omitted.

At the beginning and the end of the experiment, the heart rate and the blood pressure of each subject are in normal value ranges, no abnormal change occurs during the experiment, and the measured data are omitted.

b. Routine examination of urine, routine examination of stool, routine examination of blood

Before and after the test, the color, the character and the microscopic examination of the feces of the two groups of testees are not abnormal, the pH value, the transparency, the color and the microscopic examination of the urine of the two groups of testees are not abnormal, and the urine ketone body is negative.

Before and after the test, the measured values of blood red blood cells, white blood cells, blood platelets and hemoglobin of two groups of subjects have no abnormal change, and the test data are omitted because no significant difference exists between the pre-and post-test group comparison and the group comparison of the control group comparison.

c. Blood biochemical index test before and after test

Before and after the test, the liver and kidney function related biochemical indexes, blood sugar, uric acid and the like of two groups of subjects are in a normal range, abnormal changes are not found in the test period, and the experimental data are omitted.

d. Electrocardiogram, chest X-ray and abdominal B-ultrasound examination

The electrocardiogram, chest X-ray fluoroscopy, abdominal B-ultrasonic examination and the like of the two groups of subjects before the test are not abnormal.

e. Exercise endurance test

As shown in Table 25, there was no significant change in exercise endurance between the two groups of subjects before and after the test.

(3) Functional index determination

a. Body weight, body fat weight, overweight and body mass index

As shown in tables 26 to 30, after the test, the weight of the test subjects in the test group averagely decreases by 2.26kg, the weight of the body fat averagely decreases by 2.03kg, the percentage content of the body fat averagely decreases by 1.65%, the overweight degree averagely decreases by 3.68%, the BMI index decreases by 0.80, the above 5 indexes have significance (P is less than 0.01) in comparison difference between the test subjects before and after the test, and the decrease range of each index in the test group is also remarkably larger than that in the control group (P is less than 0.01); after the test diet, the weight and body fat weight of the test diet group are smaller than those of the control group, and the difference is significant (P < 0.05). The results show that the body weight and the fat content in the body of the subject are obviously reduced after the subject takes the test substance.

b. Subcutaneous fat thickness and girth measurements

As shown in tables 31 to 36, before the test, the subcutaneous fat thickness, waist circumference and hip circumference of 4 measurement points (right deltoid, right inferior scapular corner, right paraumbilical 3cm and anterior superior iliac spine) of the test group were not significantly different from those of the control group (P > 0.05). After the test feeding, the subcutaneous fat thickness of 4 measurement points of the test group is reduced, wherein the average drop of the right deltoid muscle is 0.73mm, the average drop of the right scapula lower corner is 0.36mm, the average drop of the right periumbilical 3cm is 1.43mm, and the average drop of the right anterior superior iliac spine is 1.46 mm; the average waist circumference and hip circumference of the test group after the test eating are reduced by 2.33cm and 2.19cm respectively.

Through statistical analysis, compared with the prior and subsequent test diets of the 6 index test diet groups, the differences are all significant (P <0.01), and the reduction range of each index of the test diet group is also significantly larger than that of the control group (P < 0.01). The results show that subcutaneous fat is significantly reduced after the subject takes the test substance.

In summary, 109 simple obese people (53 control groups and 56 test groups) meeting the test selection criteria of the test subject perform the weight-reducing function human body test feeding test, wherein the test feeding group continuously takes the weight-reducing capsules (2 times a day, 3 capsules each time) for 60 days, the control group is given placebo, and as a result, the weight of the tested subject is averagely reduced by 2.26kg, the weight of the body fat is averagely reduced by 2.03kg, the percentage content of the body fat is averagely reduced by 1.65%, the overweight is averagely reduced by 3.68%, the BMI index is reduced by 0.80, and the subcutaneous fat thickness, the waist circumference and the hip circumference of 4 measurement points are remarkably reduced. The above indexes have significance (P is less than 0.0 l) in comparison difference before and after the test feeding of the test feeding group; the decrease range of each index of the test group is larger than that of the control group, and the difference is significant (P is less than 0.0 l); the body weight, body fat weight, waist circumference and hip circumference of the test group and the control group have obvious difference after test (P is less than 0.05). The results show that the weight-losing health-care food has the weight-losing function.

At the beginning and the end of the test, the blood pressure and the heart rate of the two groups of people are in normal ranges; the other indexes comprise hemoglobin, red blood cells, white blood cells, platelets, serum total protein, serum albumin, glutamic-oxaloacetic transaminase, glutamic-pyruvic transaminase, creatinine, urea nitrogen, blood uric acid, urine ketone body, urine routine, stool routine, electrocardiogram, chest X-ray fluoroscopy, abdominal B-ultrasound and other examinations are not abnormal.

No allergic or other adverse reactions were observed during the test feeding.

The exercise endurance of the testee and the dietary factors have no obvious change before and after the test eating, and the result is integrated, which shows that the weight-losing health-care food has no adverse effect on the health of the testee.

Claims

1. The weight-losing health food is characterized by comprising the following components in parts by weight: 120-160 parts of conjugated linoleic acid glyceride composition, 50-70 parts of green tea extract, 40-60 parts of grape seed extract, 30-60 parts of xylo-oligosaccharide and 25-40 parts of auxiliary material.

2. The weight-losing health food as claimed in claim 1, which comprises the following components in parts by weight: 150 parts of conjugated linoleic acid glyceride composition, 65 parts of green tea extract, 50 parts of grape seed extract, 50 parts of xylo-oligosaccharide and 35 parts of auxiliary material.

3. The weight-losing health food as claimed in claim 1, further comprising 15 to 25 parts of a lotus leaf extract and/or 25 to 35 parts of a chia seed extract.

4. The weight-losing health food as claimed in claim 3, which comprises the following components in parts by weight: 140 parts of conjugated linoleic acid glyceride composition, 50 parts of green tea extract, 40 parts of grape seed extract, 40 parts of xylo-oligosaccharide, 20 parts of lotus leaf extract, 25 parts of chia seed extract and 35 parts of auxiliary material.

5. The diet health food of claim 1, wherein the conjugated linoleic acid glycerides composition comprises conjugated linoleic acid glycerides and one or more of corn syrup, sodium caseinate, ascorbyl palmitate, mixed tocopherol concentrate, silicon dioxide, or dipotassium hydrogen phosphate.

6. The diet health food as claimed in claim 1, wherein the conjugated linoleic acid content in said conjugated linoleic acid glyceride composition is 50.0% or more;

7. The weight-losing health food as claimed in claim 3, wherein the content of nuciferine in the lotus leaf extract is 90% or more.

8. The diet health food according to any one of claims 1 to 7, wherein the diet health food is a powder, a tablet or a capsule.

9. A method for preparing the weight-losing health food as claimed in claim 3, which comprises the steps of:

10. The method for preparing a weight-reducing health food according to claim 9, wherein:

the conjugated linoleic acid glyceride composition is prepared by the following method: mixing and emulsifying conjugated linoleic acid glyceride, corn syrup, sodium caseinate, ascorbyl palmitate, mixed tocopherol concentrate, silicon dioxide and dipotassium hydrogen phosphate, spray-drying and mixing under the conditions that the air inlet temperature is 180-200 ℃ and the air outlet temperature is 70-80 ℃ to prepare conjugated linoleic acid glyceride composition powder particles;

and/or the presence of a gas in the gas,

the chia seed extract is prepared by the following method: taking chia seeds, crushing, sieving with a 50-mesh sieve, and mixing according to a solid-liquid mass ratio of 1: adding 80% ethanol solution into the mixture for 8-10 times, and extracting for 1-2 hours each time for 2 times; centrifuging the extractive solution at 3000r/min for 10min, and mixing the supernatants; evaporating to dryness in water bath at 60 deg.C to obtain chia seed extract.